Replies to post #266853 on Avid Bioservices Inc (CDMO)

[Protector]

sunstar, no actually that troubles me:

"... Patients enrolled were those who had received no prior systemic chemotherapy treatment for their advanced disease and whose tumors expressed high levels of PD-L1 (defined as a tumor proportion score of 50 percent or more)...”

Suppose we change the thinking on this for a moment (and I have suggested this on this board already in 2011 or in 2012).

Assume for a moment that chemo therapy does more harm then good. It destroys healthy cells, causes infections and longer lasting side effects and certainly asks a price of the patient in terms of overall condition and immune vulnerability.

Then running AFTER such damage doesn't seem the best conditions to perform in. So what a luxary to be allowed to run a clinical trial Chemo alone versus I-O alone where there is no chemo in the arm under investigation.

Just think about it! And therefor PPHM MUST run clinical trials Durva+Bavi and NOT Durva+Bavi+Chemo IMO.